Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Nobuhiko Kamoshita"'
Autor:
Yuji Kashiwakura, Kazuhiro Endo, Atsushi Ugajin, Tomohiro Kikuchi, Shuji Hishikawa, Hitoyasu Nakamura, Yuko Katakai, Nemekhbayar Baatartsogt, Takafumi Hiramoto, Morisada Hayakawa, Nobuhiko Kamoshita, Shoji Yamazaki, Akihiro Kume, Harushi Mori, Naohiro Sata, Yoichi Sakata, Shin-ichi Muramatsu, Tsukasa Ohmori
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 30, Iss , Pp 502-514 (2023)
Gene therapy using adeno-associated virus (AAV)-based vectors has become a realistic therapeutic option for hemophilia. We examined the potential of a novel engineered liver-tropic AAV3B-based vector, AAV.GT5, for hemophilia B gene therapy. In vitro
Externí odkaz:
https://doaj.org/article/e60d3f3fd02c459c99665b37f69364fb
PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells
Autor:
Takafumi Hiramoto, Yuji Kashiwakura, Morisada Hayakawa, Nemekhbayar Baatartsogt, Nobuhiko Kamoshita, Tomoyuki Abe, Hiroshi Inaba, Hiroshi Nishimasu, Hideki Uosaki, Yutaka Hanazono, Osamu Nureki, Tsukasa Ohmori
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-12 (2023)
Abstract Background Base editing via CRISPR-Cas9 has garnered attention as a method for correcting disease-specific mutations without causing double-strand breaks, thereby avoiding large deletions and translocations in the host chromosome. However, i
Externí odkaz:
https://doaj.org/article/8d87658f0b3149538b80ca60fb8ca67c
Autor:
Yuji Kashiwakura, Nemekhbayar Baatartsogt, Shoji Yamazaki, Azusa Nagao, Kagehiro Amano, Nobuaki Suzuki, Tadashi Matsushita, Akihiro Sawada, Satoshi Higasa, Naoya Yamasaki, Teruhisa Fujii, Taemi Ogura, Hideyuki Takedani, Masashi Taki, Takeshi Matsumoto, Jun Yamanouchi, Michio Sakai, Masako Nishikawa, Yutaka Yatomi, Koji Yada, Keiji Nogami, Ryota Watano, Takafumi Hiramoto, Morisada Hayakawa, Nobuhiko Kamoshita, Akihiro Kume, Hiroaki Mizukami, Shizukiyo Ishikawa, Yoichi Sakata, Tsukasa Ohmori
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 27, Iss , Pp 404-414 (2022)
Adeno-associated virus (AAV) vectors are promising modalities of gene therapy to address unmet medical needs. However, anti-AAV neutralizing antibodies (NAbs) hamper the vector-mediated therapeutic effect. Therefore, NAb prevalence in the target popu
Externí odkaz:
https://doaj.org/article/b43dde9c693b47fc933baa57f7dd8461
Autor:
Nemekhbayar Baatartsogt, Yuji Kashiwakura, Morisada Hayakawa, Nobuhiko Kamoshita, Takafumi Hiramoto, Hiroaki Mizukami, Tsukasa Ohmori
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss , Pp 162-171 (2021)
Most gene therapy clinical trials that systemically administered adeno-associated virus (AAV) vector enrolled only patients without anti-AAV-neutralizing antibodies. However, laboratory tests to measure neutralizing antibodies varied among clinical t
Externí odkaz:
https://doaj.org/article/938bda7f81fd40f8a642c931f7f309c4
Autor:
Nemekhbayar Baatartsogt, Yuji Kashiwakura, Takafumi Hiramoto, Morisada Hayakawa, Nobuhiko Kamoshita, Tsukasa Ohmori
Publikováno v:
The Journal of Gene Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::580122f210bb84fa6e17c314f9d44ea8
https://doi.org/10.1002/jgm.3505
https://doi.org/10.1002/jgm.3505
Autor:
Tomoki Togashi, Nemekhbayar Baatartsogt, Yasumitsu Nagao, Yuji Kashiwakura, Morisada Hayakawa, Nobuhiko Kamoshita, Takafumi Hiramoto, Takayuki Fujiwara, Eriko Morishita, Osamu Nureki, Tsukasa Ohmori
Protein C (PC) is a plasma anticoagulant encoded byPROC; mutation in bothPROCalleles results in neonatal purpura fulminans—a fatal systemic thrombotic disorder. In the present study, we aimed to develop a genome editing treatment to cure congenital
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e772340ccd6dbbefffcaa2cf0cc07c96
https://doi.org/10.1101/2023.02.26.530058
https://doi.org/10.1101/2023.02.26.530058
Autor:
Yuji Kashiwakura, Kazuhiro Endo, Atsushi Ugajin, Tomohiro Kikuchi, Shuji Hishikawa, Hitoyasu Nakamura, Yuko Katakai, Nemekhbayar Baatartsogt, Takafumi Hiramoto, Morisada Hayakawa, Nobuhiko Kamoshita, Shoji Yamazaki, Akihiro Kume, Harushi Mori, Naohiro Sata, Yoichi Sakata, Shin-ichi Muramatsu, Tsukasa Ohmori
Gene therapy for hemophilia using adeno-associated virus (AAV) vectors allows long-term coagulation factor expression. We examined the potential of a novel engineered liver-tropic AAV3B-based vector AAV.GT5 for hemophilia B gene therapy.In vitrotrans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22afc8c6443fff2cbd346bd8eb8b42b6
https://doi.org/10.1101/2022.11.24.517886
https://doi.org/10.1101/2022.11.24.517886
Autor:
Nemekhbayar Baatartsogt, Yuji Kashiwakura, Takafumi Hiramoto, Morisada Hayakawa, Nobuhiko Kamoshita, Tsukasa Ohmori
Intravenous administration of adeno-associated virus (AAV) vector is a promising gene therapy approach for monogenic diseases. However, re-administration of the same AAV serotype is impossible due to the induction of anti-AAV neutralizing antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cad1ea1473d151f790b009ec642a9c25
https://doi.org/10.1101/2022.10.21.513281
https://doi.org/10.1101/2022.10.21.513281
Autor:
Morisada Hayakawa, Tsukasa Ohmori, Yutaka Yatomi, Atsushi Yasumoto, Hiroshi Saito, Nobuhiko Kamoshita, Katsue Suzuki-Inoue
Publikováno v:
International Journal of Hematology. 111:786-794
Platelet function tests utilizing agonists or patient serum are generally performed to assess platelet activation ex vivo. However, inter-individual differences in platelet reactivity and donor requirements make it difficult to standardize these test
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee2e11018ec8b21231d11194e8c3a138
https://doi.org/10.1007/s12185-020-02853-6
https://doi.org/10.1007/s12185-020-02853-6
Autor:
Shin-ichi Tominaga, Nobuhiko Kamoshita
Publikováno v:
RNA. 25:90-104
The translation of capsid proteins of Plautia stali intestine virus (PSIV), encoded in its second open reading frame (ORF2), is directed by an internal ribosomal entry site (IRES) located in the intergenic region (IGR). Owing to the specific properti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56b7d09b5ebd00ca096f2d48062ddcb9
https://doi.org/10.1261/rna.065466.117
https://doi.org/10.1261/rna.065466.117